• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

神经肌肉疾病中的晚期心力衰竭治疗

Advanced Heart Failure Therapies in Neuromuscular Diseases.

作者信息

Agdamag Arianne Clare, Nandar Phoo Pwint, Tang W H Wilson

机构信息

Section of Advanced Heart Failure and Transplantation Medicine, Department of Cardiovascular Medicine, Miller Family Heart, Vascular and Thoracic Institute, Robert and Suzanne Tomsich, Cleveland Clinic, Cleveland, OH 44195, USA.

Section of Advanced Heart Failure, Department of Medicine, MetroHealth Medical Center, Cleveland, OH 44109, USA.

出版信息

Curr Treat Options Cardiovasc Med. 2024 Aug;26(8):255-270. doi: 10.1007/s11936-024-01046-2. Epub 2024 Jun 25.

DOI:10.1007/s11936-024-01046-2
PMID:39777119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11706575/
Abstract

PURPOSE OF REVIEW

The main objective of this review article is to discuss the prevalence, utilization, and outcomes associated with advanced heart failure therapies among patients with neuromuscular disorders.

RECENT FINDINGS

Neuromuscular disorders often have multisystem involvement with a high prevalence of cardiovascular pathology. With the improvement in management of respiratory related complications, heart failure is now the leading cause of mortality in this patient population. Advanced heart failure therapies with durable left ventricular assist devices and heart transplantation have proven to be feasible and safe treatment options in selected patients.

SUMMARY

Management of neuromuscular disease involves multidisciplinary team involvement given the systemic nature of the disease. Early recognition and close monitoring of these patients will allow for timely initiation of advanced heart failure therapies that can lead to successful outcomes.

摘要

综述目的

本文综述的主要目的是讨论神经肌肉疾病患者中晚期心力衰竭治疗的患病率、应用情况及治疗结果。

最新发现

神经肌肉疾病常累及多系统，心血管病变的患病率很高。随着呼吸相关并发症管理的改善，心力衰竭现已成为该患者群体的主要死亡原因。对于部分选定患者，使用耐用的左心室辅助装置和心脏移植的晚期心力衰竭治疗已被证明是可行且安全的治疗选择。

总结

鉴于神经肌肉疾病的全身性，其管理需要多学科团队的参与。对这些患者的早期识别和密切监测将有助于及时启动晚期心力衰竭治疗，从而取得成功的治疗结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/b3ec3efcae8a/nihms-2006362-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/834c06b2aae6/nihms-2006362-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/770eb9a3a29e/nihms-2006362-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/d0a1136f936a/nihms-2006362-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/b3ec3efcae8a/nihms-2006362-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/834c06b2aae6/nihms-2006362-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/770eb9a3a29e/nihms-2006362-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/d0a1136f936a/nihms-2006362-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1495/11706575/b3ec3efcae8a/nihms-2006362-f0004.jpg

相似文献

1
Advanced Heart Failure Therapies in Neuromuscular Diseases.神经肌肉疾病中的晚期心力衰竭治疗
Curr Treat Options Cardiovasc Med. 2024 Aug;26(8):255-270. doi: 10.1007/s11936-024-01046-2. Epub 2024 Jun 25.
2
Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.左心室辅助装置作为晚期心力衰竭的终末期治疗的临床和成本效益：系统评价和经济评估。
Health Technol Assess. 2024 Aug;28(38):1-237. doi: 10.3310/MLFA4009.
3
Current Role of the Total Artificial Heart in the Management of Advanced Heart Failure.全人工心脏在晚期心力衰竭治疗中的作用
Curr Cardiol Rep. 2019 Nov 22;21(11):142. doi: 10.1007/s11886-019-1242-5.
4
Left ventricular assist devices: an evidence-based analysis.左心室辅助装置：基于证据的分析
Ont Health Technol Assess Ser. 2004;4(3):1-69. Epub 2004 Mar 1.
5
Heart Transplant and Ventricular Assist: Cardiac Surgery and Heart Failure Perspective.心脏移植与心室辅助：心脏外科与心力衰竭视角
US Cardiol. 2021 Sep 24;15:e16. doi: 10.15420/usc.2021.11. eCollection 2021.
6
Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices.晚期心力衰竭：左心室辅助装置不断发展领域中的治疗选择与挑战
J Cardiovasc Dev Dis. 2024 Feb 16;11(2):61. doi: 10.3390/jcdd11020061.
7
[Therapeutic options in advanced heart failure : place of durable left ventricular assist device (LVAD)].晚期心力衰竭的治疗选择：持久性左心室辅助装置（LVAD）的地位
Rev Med Suisse. 2018 May 23;14(608):1070-1077.
8
Special Considerations for Advanced Heart Failure Surgeries: Durable Left Ventricular Devices and Heart Transplantation.晚期心力衰竭手术的特殊考虑因素：耐用左心室装置与心脏移植
J Cardiovasc Dev Dis. 2024 Apr 15;11(4):119. doi: 10.3390/jcdd11040119.
9
Shared Care to Destination Therapy Left Ventricular Assist Device Site: a Novel Strategy to Start a Successful Mechanical Circulatory Support Program.共享照护至目的地治疗左心室辅助装置部位：启动成功机械循环支持计划的新策略。
Curr Cardiol Rep. 2021 Jul 15;23(8):112. doi: 10.1007/s11886-021-01533-z.
10
Advanced Heart Failure Therapies for Hypertrophic Cardiomyopathy: State-of-the-Art Review and an Updated Analysis From UNOS.肥厚型心肌病的心力衰竭治疗进展：来自 UNOS 的最新综述和分析
JACC Heart Fail. 2023 Nov;11(11):1473-1480. doi: 10.1016/j.jchf.2023.07.004. Epub 2023 Aug 23.

引用本文的文献

1
Crucial Role of Early Detection in Managing Heart Failure in Kearns-Sayre Syndrome: A Case Report.早期检测在卡恩斯-塞尔综合征心力衰竭管理中的关键作用：一例报告
Am J Case Rep. 2025 Aug 18;26:e947439. doi: 10.12659/AJCR.947439.

本文引用的文献

1
Applications of Gene Therapy in Cardiomyopathies.基因治疗在心肌病中的应用。
JACC Heart Fail. 2024 Feb;12(2):248-260. doi: 10.1016/j.jchf.2023.09.015. Epub 2023 Oct 7.
2
Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report.《神经肌肉疾病患者的呼吸管理：美国胸科学会临床实践指南和专家报告》。
Chest. 2023 Aug;164(2):394-413. doi: 10.1016/j.chest.2023.03.011. Epub 2023 Mar 13.
3
Immunogenicity and toxicity of AAV gene therapy.
AAV 基因治疗的免疫原性和毒性。
Front Immunol. 2022 Aug 12;13:975803. doi: 10.3389/fimmu.2022.975803. eCollection 2022.
4
2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.2022 HRS 专家共识声明：神经肌肉疾病中心律失常风险的评估与管理。
Heart Rhythm. 2022 Oct;19(10):e61-e120. doi: 10.1016/j.hrthm.2022.04.022. Epub 2022 Apr 29.
5
Addressing high dose AAV toxicity - 'one and done' or 'slower and lower'?应对高剂量腺相关病毒毒性——“一次性给药”还是“缓慢低剂量给药”？
Expert Opin Biol Ther. 2022 Sep;22(9):1067-1071. doi: 10.1080/14712598.2022.2060737. Epub 2022 Apr 3.
6
Dystrophic Cardiomyopathy and the Need for Cardiovascular Care.营养不良性心肌病与心血管护理需求
J Card Fail. 2022 Jun;28(6):1040-1041. doi: 10.1016/j.cardfail.2022.02.004. Epub 2022 Feb 15.
7
Cardiopulmonary exercise testing in neuromuscular disease: a systematic review.肌病心肺运动试验的系统评价。
Expert Rev Cardiovasc Ther. 2021 Nov;19(11):975-991. doi: 10.1080/14779072.2021.2009802.
8
Gene therapy for neuromuscular disorders: prospects and ethics.用于神经肌肉疾病的基因治疗：前景与伦理
Arch Dis Child. 2022 May;107(5):421-426. doi: 10.1136/archdischild-2020-320908. Epub 2021 Aug 30.
9
Early extubation after left ventricular assist device implantation in a patient with Duchenne muscular dystrophy: a case report.左心室辅助装置植入术后早期拔管治疗杜氏肌营养不良症 1 例报告。
J Anesth. 2021 Jun;35(3):455-458. doi: 10.1007/s00540-021-02925-9. Epub 2021 Mar 29.
10
Is there a future for the use of left ventricular assist devices in Duchenne muscular dystrophy?左心室辅助装置在杜氏肌营养不良症中的应用前景如何？
Pediatr Pulmonol. 2021 Apr;56(4):753-759. doi: 10.1002/ppul.25181. Epub 2020 Nov 27.